Safety and Efficacy Study of a Single Dose of NA-1 in Patients Undergoing Endovascular Repair of Ruptured Aneurysms

Exclusion Criteria

• •1\. Prior SAH within 6 months of presentation.
• •2\. Dissecting or mycotic brain aneurysm.
• •3\. Planned endovascular vessel sacrifice as the primary modality for aneurysm treatment.
• •4\. Known history of life-threatening allergic reaction to any medication.
• •5\. Chronic renal disease defined as a baseline serum creatinine \> 150 µmol/L.
• •6\. Women who are pregnant, or have a positive urine or blood (β-hCG) pregnancy test.
• •7\. Women who are breastfeeding.
• •8\. Any clinically significant psychiatric or psychological disease, which would preclude the patient from completing the protocol.
• •9\. Pre-morbid (estimated) modified Rankin scale score of \>1.
• •10\. Previous major stroke.
• •11\. Patients with known HIV infection.
• •12\. Participation in a clinical trial with an investigational drug within 30 days preceding this study.
• •13\. Previous participation in the ENACT trial (e.g, to treat a prior aneurysm), participation in another trial involving NA-1 or prior receipt of NA-1.
• •14\. Any other medical condition that the site investigator deems would put the patient at excessive risk of participation in the study or an expected life expectancy less than 1 year or that would result in inability to collect clinical outcomes at 90 days.